Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113

NCT00659971 is registered in ClinicalTrials.gov with Pacgen Biopharmaceuticals Corporation as lead sponsor.

NCT NCT00659971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00659971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113
Lead sponsor
Pacgen Biopharmaceuticals Corporation
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2008
Enrollment
223 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral candidiasis